View in EDS

Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.

Saved in:
Bibliographic Details
Title: Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.
Authors: Bates EA; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Davies JA; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Váňová J; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.; Department of Genetics and Microbiology, Faculty of Science, Charles University, Viničná 5, 128 44 Prague 2, Czech Republic., Nestić D; Division of Molecular Biology, Ruđer Bošković Institute, Bijenička cesta 54, 10000 Zagreb, Croatia., Meniel VS; European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK., Koushyar S; European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK., Cunliffe TG; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Mundy RM; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Moses E; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Uusi-Kerttula HK; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Baker AT; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Cole DK; Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Majhen D; Division of Molecular Biology, Ruđer Bošković Institute, Bijenička cesta 54, 10000 Zagreb, Croatia., Rizkallah PJ; Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK., Phesse T; European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK., Chester JD; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.; Velindre Cancer Centre, Whitchurch, Cardiff CF14 2TL, UK., Parker AL; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.
Source: Molecular therapy oncolytics [Mol Ther Oncolytics] 2022 Mar 16; Vol. 25, pp. 43-56. Date of Electronic Publication: 2022 Mar 16 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101666776 Publication Model: eCollection Cited Medium: Print ISSN: 2372-7705 (Print) Linking ISSN: 23727705 NLM ISO Abbreviation: Mol Ther Oncolytics Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35399606
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Bates+EA%22">Bates EA</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.<br /><searchLink fieldCode="AU" term="%22Davies+JA%22">Davies JA</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.<br /><searchLink fieldCode="AU" term="%22Váňová+J%22">Váňová J</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.; Department of Genetics and Microbiology, Faculty of Science, Charles University, Viničná 5, 128 44 Prague 2, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Nestić+D%22">Nestić D</searchLink>; Division of Molecular Biology, Ruđer Bošković Institute, Bijenička cesta 54, 10000 Zagreb, Croatia.<br /><searchLink fieldCode="AU" term="%22Meniel+VS%22">Meniel VS</searchLink>; European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK.<br /><searchLink fieldCode="AU" term="%22Koushyar+S%22">Koushyar S</searchLink>; European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK.<br /><searchLink fieldCode="AU" term="%22Cunliffe+TG%22">Cunliffe TG</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.<br /><searchLink fieldCode="AU" term="%22Mundy+RM%22">Mundy RM</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.<br /><searchLink fieldCode="AU" term="%22Moses+E%22">Moses E</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.<br /><searchLink fieldCode="AU" term="%22Uusi-Kerttula+HK%22">Uusi-Kerttula HK</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.<br /><searchLink fieldCode="AU" term="%22Baker+AT%22">Baker AT</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.<br /><searchLink fieldCode="AU" term="%22Cole+DK%22">Cole DK</searchLink>; Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.<br /><searchLink fieldCode="AU" term="%22Majhen+D%22">Majhen D</searchLink>; Division of Molecular Biology, Ruđer Bošković Institute, Bijenička cesta 54, 10000 Zagreb, Croatia.<br /><searchLink fieldCode="AU" term="%22Rizkallah+PJ%22">Rizkallah PJ</searchLink>; Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.<br /><searchLink fieldCode="AU" term="%22Phesse+T%22">Phesse T</searchLink>; European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK.<br /><searchLink fieldCode="AU" term="%22Chester+JD%22">Chester JD</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.; Velindre Cancer Centre, Whitchurch, Cardiff CF14 2TL, UK.<br /><searchLink fieldCode="AU" term="%22Parker+AL%22">Parker AL</searchLink>; Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101666776%22">Molecular therapy oncolytics</searchLink> [Mol Ther Oncolytics] 2022 Mar 16; Vol. 25, pp. 43-56. <i>Date of Electronic Publication: </i>2022 Mar 16 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101666776 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2372-7705 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223727705%22">23727705 </searchLink><i>NLM ISO Abbreviation: </i>Mol Ther Oncolytics <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35399606
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.omto.2022.03.007
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 43
    Titles:
      – TitleFull: Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bates EA
      – PersonEntity:
          Name:
            NameFull: Davies JA
      – PersonEntity:
          Name:
            NameFull: Váňová J
      – PersonEntity:
          Name:
            NameFull: Nestić D
      – PersonEntity:
          Name:
            NameFull: Meniel VS
      – PersonEntity:
          Name:
            NameFull: Koushyar S
      – PersonEntity:
          Name:
            NameFull: Cunliffe TG
      – PersonEntity:
          Name:
            NameFull: Mundy RM
      – PersonEntity:
          Name:
            NameFull: Moses E
      – PersonEntity:
          Name:
            NameFull: Uusi-Kerttula HK
      – PersonEntity:
          Name:
            NameFull: Baker AT
      – PersonEntity:
          Name:
            NameFull: Cole DK
      – PersonEntity:
          Name:
            NameFull: Majhen D
      – PersonEntity:
          Name:
            NameFull: Rizkallah PJ
      – PersonEntity:
          Name:
            NameFull: Phesse T
      – PersonEntity:
          Name:
            NameFull: Chester JD
      – PersonEntity:
          Name:
            NameFull: Parker AL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 16
              M: 03
              Text: 2022 Mar 16
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2372-7705
          Numbering:
            – Type: volume
              Value: 25
          Titles:
            – TitleFull: Molecular therapy oncolytics
              Type: main
ResultId 1